Web This site Trusted
8 result(s) for “if can dealing site:www.investegate.co.uk” · 466 ms
Scope: Nishi’s own index (our crawl + Common Crawl) — not the whole live web. Some sites block all automated crawlers (anti-bot walls), so their pages may be absent here even though we never filter lawful content.
Freshness: no result on this page carries a fetch time yet (indexed before the fetch epoch was stored beside the doc)
A copy of the relevant Notification of Dealing Form can be found below
from the top result below
https://www.investegate.co.uk/announcement/rns/capital-limited-di---capd/director-dealing/8815019
A copy of the relevant Notification of Dealing Form can be found below
https://www.investegate.co.uk/announcement/prn/global-opportunities-trust--got/transaction-in-own-shares/2702857
Investegate takes no responsibility for the accuracy of the information within this site
https://www.investegate.co.uk/announcement/rns/spirax-group-plc--spx/transaction-in-own-shares/1623824
Investegate takes no responsibility for the accuracy of the information within this site
https://www.investegate.co.uk/announcement/prn/global-opportunities-trust--got/total-voting-rights/889566
Investegate takes no responsibility for the accuracy of the information within this site
https://www.investegate.co.uk/announcement/rns/pod-point-group-holdings--podp/notice-of-results/8117387
Investegate takes no responsibility for the accuracy of the information within this site
https://www.investegate.co.uk/announcement/rns/supermarket-income-reit--supr/dividend-declaration/9340144
Investegate takes no responsibility for the accuracy of the information within this site
https://www.investegate.co.uk/announcement/rns/agronomics-limited--anic/further-equity-investment-in-bluenalu/9323523
The success of BlueNalu is more important than ever for Agronomics and we will do everything we can to support Lou Cooperhouse (the CEO and Founder), Lauran Madden, PhD (CTO) and the management team deliver on their business plan, which is bold and ambitious in scale and has the potential to turn BlueNalu into a very
https://www.investegate.co.uk/announcement/rns/thalia-therapeutics-plc--that/n4-101-in-vitro-results/8605772
N4 Pharma's oral IBD product, N4 101, is designed to showcase the key benefits of the Nuvec® delivery technology where other approaches struggle: i) it can straightforwardly load multiple RNA therapeutics onto the same particle, ii) it protects the payload from enzyme degradation to allow oral delivery to the gut and